Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70690 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Miguel Benjamin Cervera-Sanchez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. Hauptthemen laut MEDLINE: Psilocybin, Epilepsy, Anticonvulsants. Die Arbeit nennt 78 Literaturangaben.
Abstract (Originalsprache)
Psilocybin shows potential in neuropsychiatric disorders but has a complex relationship with epilepsy and seizures. We reviewed literature up to November 2025 to identify studies relevant to psilocybin's effects on seizures and epilepsy, including our research on serotonergic modulation. Core studies addressing the research question and supplementary mechanistic evidence were included for synthesis. Risk of bias (RoB) was assessed by study type; independent reviewers achieved strong agreement (unweighted Cohen's κ = 0.80, SE = 0.185; 99% CI 0.006–0.011; per cent agreement = 88.9%). Experimental models suggest psilocybin , through 5‐hydroxytryptamine receptor 2A ( 5-T2A ) activation, may confer antiseizure effects. Preclinical data support serotonergic modulation as a promising strategy. RoB assessment highlighted methodological challenges, suggesting cautious interpretation. Clinical evidence in neuropsychiatric populations shows no increased seizure risk under medical supervision. Psilocybin could serve as an adjunctive therapy via selective serotonergic modulation. However, conflicting evidence and concerns at high doses urge caution. Future animal studies and clinical trials must confirm psilocybin's safety and efficacy in the treatment of epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Epilepsy Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
- Department of Neurosurgery, Heidelberg University Hospital, Ruprecht Karls University of Heidelberg, Heidelberg, Germany.
- Autonomous University of Mexico State, Toluca, Mexico.
- University Center for Health Science, University of Guadalajara, Guadalajara, Mexico.
ORCID-Profile: Miguel Benjamin Cervera-Sanchez, Daniel San-Juan, Roberto Díaz-Peregrino, Evelin Zulema Camacho-Castillo, Sthefany Anahi Bringas-Ortiz, Christian Padilla-Cabezutd
Zitieren
APA
Cervera-Sanchez, M. B., San-Juan, D., Díaz-Peregrino, R., Camacho-Castillo, E. Z., Bringas-Ortiz, S. A., & Padilla-Cabezutd, C. (2026). Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70690
Vancouver
Cervera-Sanchez MB, San-Juan D, Díaz-Peregrino R, Camacho-Castillo EZ, Bringas-Ortiz SA, Padilla-Cabezutd C. Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70690
BibTeX
@article{CerveraSanchez2026,
author = {Cervera-Sanchez, Miguel Benjamin and San-Juan, Daniel and Díaz-Peregrino, Roberto and Camacho-Castillo, Evelin Zulema and Bringas-Ortiz, Sthefany Anahi and Padilla-Cabezutd, Christian},
title = {Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70690}
}
EUVIMED